News | Women's Health | July 11, 2018

Breast Cancer Studies Ignore Race, Socioeconomic Factors

New analysis of breast cancer studies published in 2016 found that fewer than five percent were stratified by race, socioeconomic factors

Breast Cancer Studies Ignore Race, Socioeconomic Factors

July 11, 2018 — A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help determine people’s vulnerability to cancer. The commentary, by scientists from the Bloomberg School, also argues that these factors should be considered routinely in studies and risk assessments that bear on clinical care.

"We've been missing opportunities to understand and reduce disparities in breast cancer risk and outcomes," said lead author Lorraine T. Dean, ScD, an assistant professor in the Department of Epidemiology at the Bloomberg School. "Simply put, not enough is being done to understand how race, income level and other social factors tie in to cancer susceptibility."

A 2014 review of over 20 years of National Cancer Institute clinical trials, for example, found that only about 20 percent of the randomized controlled studies reported results stratified by race/ethnicity. In a follow-up analysis of 57 breast cancer observational and randomized controlled trials that were published in 2016, the researchers found that, after excluding those in which the primary focus was disparities, fewer than 5 percent of studies reported findings stratified by race or other socioeconomic factors.

As Dean and colleagues note in their commentary, it should be obvious that in general, neglecting race/ethnicity and other social factors in medical research can mask important drivers of bad outcomes. For example, a recent high-profile study sorting mortality rates by race and socioeconomic status revealed that midlife mortality is increasing among blue-collar whites in the U.S. even though it is declining for the population overall. Those findings drew attention to ongoing increases in suicides and substance-abuse-related deaths for blue-collar whites, and led researchers to zero in on economic despair and social decay as the likely causes.

"A lot of scientists don't want to deal with race or socioeconomic position in their studies because they think those characteristics aren't modifiable," Dean said. "But they can actually help identify factors that are modifiable. You can't change your genes, for example, but we still do genetic studies because they illuminate pathways we can change with medicines or other interventions."

Breast cancers are the principal research focus for Dean and colleagues. They see the potential —and many missed opportunities to date —for research to uncover or at least address social-related risk factors for this set of diseases.

They point out, for example, that standard breast cancer risk assessment tools have not always taken race into account — even though there are significant racial disparities in the risks for certain types of breast cancer as well as breast cancer mortality rates. For many years, a commonly used questionnaire tool for assessing breast cancer risk (now known simply as the Breast Cancer Risk Assessment Tool) was validated only for white women. It tended to underestimate significantly the risks of breast cancers for black women, who have lower rates of mammogram screening and higher rates of breast cancer at younger ages. That error may have kept many black women from participating in cancer-prevention trials of drugs such as tamoxifen.

"The model was revised in 2015 to take race into account, and now estimates black female eligibility for chemoprevention at nearly three times the rate of the original model," said Dean.

Clinical trials and population studies should be powerful tools for uncovering links between social factors and cancer vulnerability, which in turn should lead to better risk reduction and/or treatment strategies. But here too, the necessary information is not routinely gathered.

To address the issue, Dean and her colleagues recommend:

  • Increasing education and awareness about the importance of inclusion of social factors in clinical research;
  • Adding requirements for data on social factors to journal guidelines for reporting study results; and
  • Refining cancer risk assessment tools by including social factors.

"If adopted, these measures would enable more effective design and implementation of interventions," Dean said, "and would help eliminate breast cancer racial and socioeconomic disparities by accounting for the social and environmental contexts in which cancer patients live and are treated."

For more information: www.link.springer.com

Reference

Dean L.T., Gehlert S., Neuhouser M.L., et al. "Social factors matter in cancer risk and survivorship." Cancer Causes & Control, May 30, 2018. https://doi.org/10.1007/s10552-018-1043-y

Related Content

#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 09, 2021
April 9, 2021 — According to an open-acc...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

Ultrasound is an invaluable diagnostic tool for the early detection of breast cancer, but the classification of lesions is sometimes challenging and time consuming. Could artificial intelligence hold the answer to solving these problems? Graphic courtesy of Chinese Medical Journal

News | Artificial Intelligence | April 06, 2021
April 6, 2021 — In 2020, the International Agency for Research on...
While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to discover new approaches to saving lives. A study published in the JAMA Network Open on Thursday, March 25, 2021, recommends a new way for triaging mammogram patients during times of limited capacity, such as pandemic surges, when individuals may also experience anxiety about COVID-19.

Getty Images

News | Breast Imaging | April 01, 2021
April 1, 2021 — While the COVID-19 crisis is challenging, the pandemic is also giving researchers an opportunity to d
In looking at the broader impact of the COVID-19 pandemic on health and wellbeing, public health experts are examining screening rates for cancer. A new study looking at U.S. mammography screening rates during the first five months of the pandemic found both a strong rebound in breast cancer screening rates and a concerning cumulative deficit in mammograms due to missed appointments, as well as uncovering disparities when looking at screening according to race

Getty Images

News | Breast Imaging | April 01, 2021
April 1, 2021 — In looking at the broader impact of the...